Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;45(1):97-108.
doi: 10.1007/s12016-012-8348-5.

Late-onset inflammatory adverse reactions related to soft tissue filler injections

Affiliations
Review

Late-onset inflammatory adverse reactions related to soft tissue filler injections

Jaume Alijotas-Reig et al. Clin Rev Allergy Immunol. 2013 Aug.

Abstract

An ever-increasing number of persons seek medical solutions to improve the appearance of their aging skin or for aesthetic and cosmetic indications in diverse pathological conditions, such as malformations, trauma, cancer, and orthopedic, urological, or ophthalmological conditions. Currently, physicians have many different types of dermal and subdermal fillers, such as non-permanent, permanent, reversible, or non-reversible materials. Despite the claims of manufacturers and different authors that fillers are non-toxic and non-immunogenic or that complications are very uncommon, unwanted side effects do occur with all compounds used. Implanted, injected, and blood-contact biomaterials trigger a wide variety of adverse reactions, including inflammation, thrombosis, and excessive fibrosis. Usually, these adverse reactions are associated with the accumulation of large numbers of mononuclear cells. The adverse reactions related to fillers comprise a broad range of manifestations, which may appear early or late and range from local to systemic. Clinicians should be aware of them since the patient often denies the antecedent of injection or is unaware of the material employed. Most of these adverse effects seem to have an immunological basis, the fillers acting more as adjuvants than as direct T-cell activators, on a background of genetic predisposition. Their treatment has not been the subject of well-designed studies; management of both acute and systemic reactions is often difficult, and requires anti-inflammatory and occasionally immunosuppressive therapy. The clinical, pathological, and therapeutic aspects of inflammatory and immune-mediated late-onset adverse reactions related to soft tissue filler injections are thoroughly reviewed herein.

PubMed Disclaimer

References

    1. Dermatol Surg. 1998 Dec;24(12):1317-25 - PubMed
    1. J Am Acad Dermatol. 1994 Oct;31(4):626-42 - PubMed
    1. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):77S-84S - PubMed
    1. Dermatol Surg. 2012 Jan;38(1):38-47 - PubMed
    1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Jul;94(1):65-73 - PubMed

MeSH terms

Substances

LinkOut - more resources